Massachusetts man sues Novo Nordisk over Ozempic-linked permanent blindness
A Massachusetts father, Edward Gillen, filed a lawsuit in a U. S. federal court in Pennsylvania alleging that the GLP-1 diabetes medication Ozempic caused non-arteritic anterior ischemic optic neuropathy, leaving him legally blind. The complaint adds his case to more than 200 lawsuits nationwide that claim the drug and related GLP-1 products can cause permanent vision loss.
Earlier filings have linked other GLP-1 drugs such as Wegovy and Mounjaro to the same rare eye condition, with plaintiffs across several states accusing Novo Nordisk and Eli Lilly of failing to warn users. The manufacturers and regulators have responded that scientific evidence does not establish a causal link. The litigation began with individual plaintiffs, including a Georgia father of four, and has grown into a multi-state effort.
